Subscribe
bee32
bee32 / iStockphoto.com
13 March 2018Americas

Allergan and tribe claim PTAB can’t decide on Restasis patents

Allergan and the Saint Regis Mohawk Tribe have argued that the Patent Trial and Appeal Board (PTAB) doesn’t have the jurisdiction to decide on the validity of patents concerning a dry-eye treatment while its recent decision is being appealed.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Federal Circuit agrees with PTAB in optical patent appeal
21 January 2021   The US Court of Appeals for the Federal Circuit has affirmed a decision by the US Patent Trial and Appeal Board which centered on the validity of a patent for an ophthalmic illuminator.
Americas
Allergan and tribe to appeal PTAB’s immunity decision
2 March 2018   The Saint Regis Mohawk Tribe and Allergan are planning to appeal against the Patent Trial and Appeal Board’s decision rejecting tribal sovereign immunity.
Americas
Native American tribe not entitled to sovereign immunity: PTAB
26 February 2018   The Patent Trial and Appeal Board rejected the Saint Regis Mohawk Tribe’s attempt to dismiss inter partes reviews related to dry-eye treatment Restasis late last week.


Editor's picks

Astellas win strengthens blockbuster drug's European position
Europe
Astellas win strengthens blockbuster drug's European position
20 August 2025

Editor's picks

Europe
Astellas win strengthens blockbuster drug's European position
20 August 2025
Americas
Latham steps into dispute over $6bn treatment, replacing Kirkland
13 August 2025
Americas
BMS blocks biosimilar version of blockbuster cancer drug in India
21 July 2025
Europe
In-house with Bayer: ‘Focus on quality early and stay close to inventors’
15 July 2025
Africa
Explainer: ARIPO’s role in Plant Variety Protection
15 July 2025
Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025

More on this story

Americas
Federal Circuit agrees with PTAB in optical patent appeal
21 January 2021   The US Court of Appeals for the Federal Circuit has affirmed a decision by the US Patent Trial and Appeal Board which centered on the validity of a patent for an ophthalmic illuminator.
Americas
Allergan and tribe to appeal PTAB’s immunity decision
2 March 2018   The Saint Regis Mohawk Tribe and Allergan are planning to appeal against the Patent Trial and Appeal Board’s decision rejecting tribal sovereign immunity.
Americas
Native American tribe not entitled to sovereign immunity: PTAB
26 February 2018   The Patent Trial and Appeal Board rejected the Saint Regis Mohawk Tribe’s attempt to dismiss inter partes reviews related to dry-eye treatment Restasis late last week.

More on this story

Americas
Federal Circuit agrees with PTAB in optical patent appeal
21 January 2021   The US Court of Appeals for the Federal Circuit has affirmed a decision by the US Patent Trial and Appeal Board which centered on the validity of a patent for an ophthalmic illuminator.
Americas
Allergan and tribe to appeal PTAB’s immunity decision
2 March 2018   The Saint Regis Mohawk Tribe and Allergan are planning to appeal against the Patent Trial and Appeal Board’s decision rejecting tribal sovereign immunity.
Americas
Native American tribe not entitled to sovereign immunity: PTAB
26 February 2018   The Patent Trial and Appeal Board rejected the Saint Regis Mohawk Tribe’s attempt to dismiss inter partes reviews related to dry-eye treatment Restasis late last week.

More features

The rise of pro-NPE and patent sentiment in the US
UPC sees rising small molecule litigation with Pfizer in the hot seat
Why the Caribbean cannabis economy is ripe for IP protection
China filings push rise in patent applications in Ireland
Brain disorder medtech rivals butt heads at ITC
The right formula: Minimising the cost of chemical and pharma patents
‘This is not a rescue deal’: How an acquisition fits London firm's plan
Alston & Bird partner with strong Japanese ties jumps to new firm